102677
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
利用 18F-FDG PET/CT、磁共振成像（MRI）和肿瘤标志物预测胶质瘤复发：一种综合方法
Authors Wei J
Received 5 February 2025
Accepted for publication 18 April 2025
Published 5 May 2025 Volume 2025:18 Pages 2429—2438
DOI http://doi.org/10.2147/IJGM.S520876
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ching-Hsien Chen
Jingsong Wei
Department of Neurosurgery, Northern Theater General Hospital, Shenyang, Liaoning Province, 110016, People’s Republic of China
Correspondence: Jingsong Wei, Email njas684@163.com
Objective: To evaluate the combined predictive value of 18F-FDG PET/CT, MRI, and tumor markers for glioma recurrence.
Methods: A retrospective analysis was conducted on the clinical data of 82 glioma patients treated at our hospital from January 2023 to April 2024. Patients were divided into Group A (n = 19, recurrence) and Group B (n = 63, no recurrence) based on whether recurrence occurred. All patients underwent 18F-FDG PET/CT to obtain maximum standardized uptake value (SUVmax) and lesion-to-normal tissue ratio (L/N). MRI was performed to measure the apparent diffusion coefficient (ADC) of the tumor parenchyma and cerebral blood flow (CBF). Serum samples were collected from all patients, and tumor markers, including monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR), were measured using an automated blood analyzer. Differences in SUVmax, L/N, ADC, CBF, MLR, and NLR levels between Groups A and B were compared. Spearman correlation analysis was used to assess the relationships between SUVmax, L/N, ADC, CBF, MLR, NLR, and glioma recurrence. Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value of each parameter for glioma recurrence.
Results: Recurrent patients demonstrated significantly higher SUVmax, L/N, NLR, and MLR, alongside lower ADC and CBF (all P < 0.05). These parameters correlated with recurrence (SUVmax, L/N, NLR, MLR positively; ADC and CBF negatively; all P < 0.05). ROC analysis highlighted the superiority of combined modalities, achieving an AUC of 0.856, with higher sensitivity and specificity than individual markers.
Conclusion: SUVmax, L/N, ADC, CBF, MLR, and NLR are correlated with glioma recurrence. The combined use of SUVmax, L/N, ADC, CBF, MLR, and NLR provides higher diagnostic value for glioma recurrence.
Keywords: 18F-FDG PET/CT, MRI, tumor markers, glioma, recurrence, correlation, predictive value
